Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, protein-synthesis inhibitors, tetracycline derivatives | 2661 | 220620-09-7 |
Dose | Unit | Route |
---|---|---|
0.10 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 295 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 22 % | Benet LZ, Broccatelli F, Oprea TI |
BA (Bioavailability) | 0 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 12 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 3.80 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.20 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 48 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
June 15, 2005 | FDA | PF PRISM CV |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pathogen resistance | 222.08 | 27.95 | 57 | 3790 | 5632 | 50595645 |
Pancreatitis acute | 159.37 | 27.95 | 62 | 3785 | 23750 | 50577527 |
Pancreatitis | 124.70 | 27.95 | 62 | 3785 | 42552 | 50558725 |
Drug resistance | 111.47 | 27.95 | 45 | 3802 | 18944 | 50582333 |
Hypofibrinogenaemia | 84.02 | 27.95 | 19 | 3828 | 1093 | 50600184 |
Thrombocytopenia | 80.49 | 27.95 | 71 | 3776 | 127602 | 50473675 |
Multiple organ dysfunction syndrome | 65.05 | 27.95 | 43 | 3804 | 50294 | 50550983 |
Sepsis | 52.00 | 27.95 | 57 | 3790 | 132868 | 50468409 |
Septic shock | 48.89 | 27.95 | 38 | 3809 | 57137 | 50544140 |
Klebsiella infection | 45.48 | 27.95 | 18 | 3829 | 7176 | 50594101 |
Adjusted calcium decreased | 45.35 | 27.95 | 8 | 3839 | 126 | 50601151 |
Morganella infection | 44.21 | 27.95 | 10 | 3837 | 575 | 50600702 |
Biloma | 43.59 | 27.95 | 7 | 3840 | 60 | 50601217 |
Haemodynamic instability | 43.57 | 27.95 | 18 | 3829 | 8006 | 50593271 |
Globulins decreased | 41.39 | 27.95 | 8 | 3839 | 212 | 50601065 |
Haemostasis | 40.46 | 27.95 | 8 | 3839 | 239 | 50601038 |
Systemic inflammatory response syndrome | 40.40 | 27.95 | 15 | 3832 | 5034 | 50596243 |
Coma hepatic | 38.38 | 27.95 | 9 | 3838 | 607 | 50600670 |
Vomiting | 38.38 | 27.95 | 98 | 3749 | 460660 | 50140617 |
Deafness | 37.63 | 27.95 | 20 | 3827 | 15671 | 50585606 |
Blood urea increased | 37.54 | 27.95 | 23 | 3824 | 23562 | 50577715 |
Hepatotoxicity | 36.95 | 27.95 | 24 | 3823 | 27202 | 50574075 |
Wound haemorrhage | 35.79 | 27.95 | 11 | 3836 | 2079 | 50599198 |
Immunosuppressant drug level increased | 35.49 | 27.95 | 12 | 3835 | 3070 | 50598207 |
Multiple-drug resistance | 34.63 | 27.95 | 12 | 3835 | 3302 | 50597975 |
Hepatic failure | 33.24 | 27.95 | 24 | 3823 | 32259 | 50569018 |
Pain | 33.17 | 27.95 | 3 | 3844 | 578900 | 50022377 |
Blood fibrinogen decreased | 32.74 | 27.95 | 8 | 3839 | 643 | 50600634 |
Drug ineffective | 32.42 | 27.95 | 135 | 3712 | 819198 | 49782079 |
Agranulocytosis | 31.84 | 27.95 | 20 | 3827 | 21401 | 50579876 |
Acinetobacter infection | 30.88 | 27.95 | 9 | 3838 | 1418 | 50599859 |
Nephropathy toxic | 30.49 | 27.95 | 14 | 3833 | 8015 | 50593262 |
Nausea | 30.05 | 27.95 | 119 | 3728 | 705279 | 49895998 |
Enterococcal infection | 29.28 | 27.95 | 13 | 3834 | 6885 | 50594392 |
Escherichia infection | 29.24 | 27.95 | 15 | 3832 | 10926 | 50590351 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pathogen resistance | 189.86 | 25.99 | 66 | 5056 | 8050 | 29561355 |
Hypofibrinogenaemia | 146.84 | 25.99 | 37 | 5085 | 1464 | 29567941 |
Septic shock | 138.36 | 25.99 | 102 | 5020 | 62458 | 29506947 |
Drug ineffective | 131.25 | 25.99 | 228 | 4894 | 362942 | 29206463 |
Drug resistance | 110.71 | 25.99 | 60 | 5062 | 21480 | 29547925 |
Multiple organ dysfunction syndrome | 98.75 | 25.99 | 84 | 5038 | 63032 | 29506373 |
Klebsiella infection | 95.88 | 25.99 | 39 | 5083 | 7310 | 29562095 |
Sepsis | 72.25 | 25.99 | 105 | 5017 | 142577 | 29426828 |
Thrombocytopenia | 66.47 | 25.99 | 98 | 5024 | 134725 | 29434680 |
Treatment failure | 65.67 | 25.99 | 53 | 5069 | 36886 | 29532519 |
Enterococcal infection | 59.75 | 25.99 | 29 | 5093 | 8239 | 29561166 |
Deafness neurosensory | 56.53 | 25.99 | 20 | 5102 | 2558 | 29566847 |
Mycobacterium chelonae infection | 54.58 | 25.99 | 14 | 5108 | 594 | 29568811 |
Pancreatitis acute | 49.82 | 25.99 | 38 | 5084 | 24347 | 29545058 |
Ototoxicity | 45.50 | 25.99 | 15 | 5107 | 1550 | 29567855 |
Pancreatitis | 44.05 | 25.99 | 41 | 5081 | 34473 | 29534932 |
Fungaemia | 40.62 | 25.99 | 15 | 5107 | 2166 | 29567239 |
Clostridium difficile colitis | 39.53 | 25.99 | 26 | 5096 | 13186 | 29556219 |
Myasthenia gravis crisis | 37.77 | 25.99 | 10 | 5112 | 481 | 29568924 |
Coagulopathy | 36.77 | 25.99 | 28 | 5094 | 17879 | 29551526 |
Gallstone ileus | 36.73 | 25.99 | 6 | 5116 | 22 | 29569383 |
Candida infection | 36.19 | 25.99 | 26 | 5096 | 15199 | 29554206 |
Off label use | 34.40 | 25.99 | 122 | 5000 | 300678 | 29268727 |
Product use in unapproved indication | 34.14 | 25.99 | 57 | 5065 | 86818 | 29482587 |
Multiple-drug resistance | 32.20 | 25.99 | 15 | 5107 | 3885 | 29565520 |
Staphylococcal infection | 32.13 | 25.99 | 32 | 5090 | 29208 | 29540197 |
Flavobacterium infection | 30.01 | 25.99 | 6 | 5116 | 80 | 29569325 |
Nausea | 29.41 | 25.99 | 113 | 5009 | 289142 | 29280263 |
Geotrichum infection | 29.22 | 25.99 | 8 | 5114 | 437 | 29568968 |
Anuria | 29.08 | 25.99 | 19 | 5103 | 9522 | 29559883 |
Drug reaction with eosinophilia and systemic symptoms | 27.78 | 25.99 | 29 | 5093 | 27963 | 29541442 |
Acoustic neuroma | 26.57 | 25.99 | 6 | 5116 | 147 | 29569258 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Pathogen resistance | 325.71 | 25.64 | 102 | 7989 | 12441 | 64478200 |
Drug resistance | 201.71 | 25.64 | 95 | 7996 | 35007 | 64455634 |
Septic shock | 176.58 | 25.64 | 128 | 7963 | 105309 | 64385332 |
Pancreatitis acute | 166.61 | 25.64 | 89 | 8002 | 42766 | 64447875 |
Hypofibrinogenaemia | 152.43 | 25.64 | 37 | 8054 | 1741 | 64488900 |
Drug ineffective | 151.72 | 25.64 | 327 | 7764 | 839920 | 63650721 |
Klebsiella infection | 135.68 | 25.64 | 54 | 8037 | 13227 | 64477414 |
Thrombocytopenia | 133.76 | 25.64 | 152 | 7939 | 223649 | 64266992 |
Multiple organ dysfunction syndrome | 125.64 | 25.64 | 103 | 7988 | 101310 | 64389331 |
Sepsis | 112.18 | 25.64 | 141 | 7950 | 230200 | 64260441 |
Pancreatitis | 105.68 | 25.64 | 75 | 8016 | 59532 | 64431109 |
Enterococcal infection | 77.94 | 25.64 | 37 | 8054 | 13829 | 64476812 |
Acinetobacter infection | 72.48 | 25.64 | 22 | 8069 | 2407 | 64488234 |
Coagulopathy | 67.98 | 25.64 | 45 | 8046 | 31875 | 64458766 |
Multiple-drug resistance | 58.01 | 25.64 | 24 | 8067 | 6478 | 64484163 |
Hepatotoxicity | 56.68 | 25.64 | 44 | 8047 | 39918 | 64450723 |
Blood fibrinogen decreased | 55.74 | 25.64 | 16 | 8075 | 1442 | 64489199 |
Mycobacterium chelonae infection | 53.83 | 25.64 | 17 | 8074 | 2120 | 64488521 |
Off label use | 53.34 | 25.64 | 187 | 7904 | 632619 | 63858022 |
Blood urea increased | 50.75 | 25.64 | 43 | 8048 | 44110 | 64446531 |
Ototoxicity | 49.78 | 25.64 | 17 | 8074 | 2706 | 64487935 |
Treatment failure | 49.66 | 25.64 | 67 | 8024 | 116749 | 64373892 |
Pain | 48.99 | 25.64 | 6 | 8085 | 553505 | 63937136 |
Clostridium difficile colitis | 45.32 | 25.64 | 33 | 8058 | 27190 | 64463451 |
Morganella infection | 42.79 | 25.64 | 12 | 8079 | 994 | 64489647 |
Deafness neurosensory | 42.01 | 25.64 | 19 | 8072 | 6355 | 64484286 |
Haemodynamic instability | 41.72 | 25.64 | 25 | 8066 | 14887 | 64475754 |
Pseudomonas infection | 39.98 | 25.64 | 26 | 8065 | 17857 | 64472784 |
Adjusted calcium decreased | 39.73 | 25.64 | 8 | 8083 | 156 | 64490485 |
Drug reaction with eosinophilia and systemic symptoms | 39.53 | 25.64 | 41 | 8050 | 54176 | 64436465 |
Product use in unapproved indication | 38.78 | 25.64 | 75 | 8016 | 176543 | 64314098 |
Nephropathy toxic | 38.02 | 25.64 | 25 | 8066 | 17489 | 64473152 |
Pneumonia pseudomonal | 36.77 | 25.64 | 16 | 8075 | 4887 | 64485754 |
Fall | 35.69 | 25.64 | 5 | 8086 | 416821 | 64073820 |
Haemostasis | 35.52 | 25.64 | 8 | 8083 | 270 | 64490371 |
Myasthenia gravis crisis | 35.14 | 25.64 | 10 | 8081 | 874 | 64489767 |
Biloma | 34.14 | 25.64 | 7 | 8084 | 150 | 64490491 |
Fungaemia | 33.86 | 25.64 | 14 | 8077 | 3771 | 64486870 |
Coma hepatic | 33.80 | 25.64 | 10 | 8081 | 1002 | 64489639 |
Globulins decreased | 33.16 | 25.64 | 8 | 8083 | 366 | 64490275 |
Klebsiella bacteraemia | 32.83 | 25.64 | 12 | 8079 | 2328 | 64488313 |
Headache | 32.39 | 25.64 | 13 | 8078 | 529454 | 63961187 |
Aspergillus infection | 32.24 | 25.64 | 22 | 8069 | 16357 | 64474284 |
Renal failure | 31.48 | 25.64 | 70 | 8021 | 181618 | 64309023 |
Flavobacterium infection | 31.22 | 25.64 | 6 | 8085 | 91 | 64490550 |
Immunosuppressant drug level increased | 30.79 | 25.64 | 16 | 8075 | 7243 | 64483398 |
Hepatitis cholestatic | 30.47 | 25.64 | 19 | 8072 | 12136 | 64478505 |
Hepatic failure | 30.22 | 25.64 | 36 | 8055 | 55358 | 64435283 |
Endocarditis | 29.59 | 25.64 | 17 | 8074 | 9361 | 64481280 |
Staphylococcal infection | 29.41 | 25.64 | 34 | 8057 | 50644 | 64439997 |
Hypertriglyceridaemia | 29.32 | 25.64 | 18 | 8073 | 11187 | 64479454 |
Escherichia infection | 28.97 | 25.64 | 20 | 8071 | 15148 | 64475493 |
Candida infection | 28.93 | 25.64 | 27 | 8064 | 31392 | 64459249 |
Acute kidney injury | 28.85 | 25.64 | 122 | 7969 | 449118 | 64041523 |
Electrocardiogram QT prolonged | 28.45 | 25.64 | 42 | 8049 | 79406 | 64411235 |
Wound haemorrhage | 28.37 | 25.64 | 12 | 8079 | 3419 | 64487222 |
Systemic inflammatory response syndrome | 28.22 | 25.64 | 17 | 8074 | 10218 | 64480423 |
Abdominal infection | 26.73 | 25.64 | 11 | 8080 | 2929 | 64487712 |
Pneumonia klebsiella | 26.50 | 25.64 | 12 | 8079 | 4025 | 64486616 |
Liver abscess | 26.37 | 25.64 | 13 | 8078 | 5267 | 64485374 |
Acinetobacter bacteraemia | 26.35 | 25.64 | 6 | 8085 | 213 | 64490428 |
Eosinophilic pneumonia acute | 26.32 | 25.64 | 8 | 8083 | 879 | 64489762 |
Geotrichum infection | 26.05 | 25.64 | 8 | 8083 | 910 | 64489731 |
Acoustic neuroma | 25.88 | 25.64 | 6 | 8085 | 231 | 64490410 |
None
Source | Code | Description |
---|---|---|
ATC | J01AA12 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE TETRACYCLINES Tetracyclines |
FDA CS | M0021223 | Tetracyclines |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D011500 | Protein Synthesis Inhibitors |
FDA EPC | N0000175938 | Tetracycline-class Antibacterial |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Pneumonia due to Streptococcus | indication | 34020007 | |
Haemophilus influenzae pneumonia | indication | 70036007 | |
Abdominal abscess | indication | 75100008 | |
Infectious disease of abdomen | indication | 128070006 | |
Complicated appendicitis | indication | 418171008 | |
Complicated Skin and Skin Structure E. Coli Infection | indication | ||
Complicated Skin and Skin Structure Staphylococcus Aureus Infection | indication | ||
Complicated Skin and Skin Structure Infection | indication | ||
Complicated Skin and Skin Structure Streptococcus Pyogenes Infection | indication | ||
Legionella Pneumophila Pneumonia | indication | ||
Complicated Bacterial Peritonitis | indication | ||
Complicated Skin and Skin Structure Enterococcus Faecalis Infection | indication | ||
Complicated Skin and Skin Structure Streptococcus Agalactiae Infection | indication | ||
Hyperbilirubinemia | contraindication | 14783006 | DOID:2741 |
Gastrointestinal perforation | contraindication | 51875005 | |
Hepatic failure | contraindication | 59927004 | |
Pancreatitis | contraindication | 75694006 | DOID:4989 |
Pregnancy, function | contraindication | 289908002 | |
Pseudomembranous enterocolitis | contraindication | 397683000 | |
Antibiotic-Induced Hypoprothrombinemia | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 3.13 | acidic |
pKa2 | 8.64 | acidic |
pKa3 | 11.14 | acidic |
pKa4 | 11.96 | acidic |
pKa5 | 13.08 | acidic |
pKa6 | 13.93 | acidic |
pKa7 | 9.41 | Basic |
pKa8 | 7.96 | Basic |
pKa9 | 7.31 | Basic |
None
None
None
ID | Source |
---|---|
4024922 | VUID |
N0000171604 | NUI |
D01079 | KEGG_DRUG |
4024922 | VANDF |
C1260298 | UMLSCUI |
CHEBI:142708 | CHEBI |
T1C | PDB_CHEM_ID |
CHEMBL376140 | ChEMBL_ID |
D000078304 | MESH_DESCRIPTOR_UI |
DB00560 | DRUGBANK_ID |
C087533 | MESH_SUPPLEMENTAL_RECORD_UI |
10929 | IUPHAR_LIGAND_ID |
8115 | INN_ID |
70JE2N95KR | UNII |
54686904 | PUBCHEM_CID |
384455 | RXNORM |
20166 | MMSL |
230306 | MMSL |
69774 | MMSL |
d05537 | MMSL |
010833 | NDDF |
418313005 | SNOMEDCT_US |
418631002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Tygacil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0008-4990 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | NDA | 33 sections |
Tygacil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0008-4994 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | NDA | 30 sections |
Tigecycline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0781-3481 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 26 sections |
TIGECYCLINE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 16729-364 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | NDA | 31 sections |
Tigecycline | Human Prescription Drug Label | 1 | 55150-228 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 27 sections |
Tigecycline | Human Prescription Drug Label | 1 | 55150-228 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 27 sections |
Tigecycline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-6098 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 27 sections |
Tigecycline | Human Prescription Drug Label | 1 | 63323-960 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | NDA | 27 sections |
Tigecycline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70121-1647 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | NDA | 22 sections |
Tigecycline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70594-035 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 33 sections |
Tigecycline | HUMAN PRESCRIPTION DRUG LABEL | 1 | 71288-019 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 50 mg | INTRAVENOUS | ANDA | 30 sections |